Insulin-Like Growth Factor Binding Protein 5-A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2019 Dec 31

PMID 31886201

Citations 9

Authors

Shuqiang Wang

Quan Hong

Xiaodong Geng

Kun Chi

Guangyan Cai

Di Wu

Affiliations

Soon will be listed here.

Abstract

Kidney renal papillary renal cell carcinoma (KIRP) accounts for 10-15% of renal cell carcinoma (RCC). The need to find more therapeutic targets for KIRP is urgent because most targeted drugs have limited effects on advanced KIRP. Insulin-like growth factor (IGF) binding protein 5 (IGFBP5) is a secreted protein related to cell proliferation, cell adhesion, cell migration, the inflammatory response and fibrosis; these functions are independent of IGF. In our study, we determined the expression and functions of IGFBP5 with data from the database of The Cancer Genome Atlas (TCGA). We found that IGFBP5 is down regulated in KIRP kidney tissues compared to its expression in control tissues and that the expression of IGFBP5 is negatively related to patient survival. Bioinformatic analysis showed the probable processes and pathways involved in altered IGFBP5 expression, including blood vessel development, the cellular response to growth factor stimulus, the response to transforming growth factor (TGF-), and extracellular matrix organization. We proposed that VEGFA and TGF- act as upstream regulatory factors of IGFBP5 and verified this in the Caki-2 cell line. Based on our results, we suggest that IGFBP5 might be a therapeutic target of KIRP.

Citing Articles

Identification of prognostic stemness-related genes in kidney renal papillary cell carcinoma.

Liu Y, Yao Y, Zhang Y, Xu C, Yang T, Qu M BMC Med Genomics. 2024; 17(1):121.

PMID: 38702698 PMC: 11067181. DOI: 10.1186/s12920-024-01870-2.

Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhibiting insulin-like growth factor 1 receptor/protein kinase B pathway in acute myeloid leukemia.

Zhang B, Deng X, You R, Liu J, Hou D, Wang X Neoplasia. 2023; 47:100952.

PMID: 38159363 PMC: 10829870. DOI: 10.1016/j.neo.2023.100952.

Expression characteristics and their functional role of IGFBP gene family in pan-cancer.

Liu Y, Shen S, Yan Z, Yan L, Ding H, Wang A BMC Cancer. 2023; 23(1):371.

PMID: 37088808 PMC: 10124011. DOI: 10.1186/s12885-023-10832-3.

Insulin-like growth factor binding protein 5b of and its heparin-binding motif play a critical role in host antibacterial immune responses NF-κB pathway.

Du H, Zhou Y, Du X, Zhang P, Cao Z, Sun Y Front Immunol. 2023; 14:1126843.

PMID: 36865533 PMC: 9972581. DOI: 10.3389/fimmu.2023.1126843.

Insulin-like growth factor binding protein 5: Diverse roles in cancer.

A Waters J, Urbano I, Robinson M, House C Front Oncol. 2022; 12:1052457.

PMID: 36465383 PMC: 9714447. DOI: 10.3389/fonc.2022.1052457.

References

Butt A, Dickson K, McDougall F, Baxter R . Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem. 2003; 278(32):29676-85. DOI: 10.1074/jbc.M301965200. View

Smith B, Bhowmick N . Role of EMT in Metastasis and Therapy Resistance. J Clin Med. 2016; 5(2). PMC: 4773773. DOI: 10.3390/jcm5020017. View

Hutson T, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A . Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010; 46(13):2432-40. DOI: 10.1016/j.ejca.2010.06.121. View

Hwang J, Huh J, Lee Y, Lee S, Rho S, Lee J . Insulin-like growth factor-binding protein-5 (IGFBP-5) inhibits TNF-α-induced NF-κB activity by binding to TNFR1. Biochem Biophys Res Commun. 2011; 405(4):545-51. DOI: 10.1016/j.bbrc.2011.01.064. View

Colak S, Ten Dijke P . Targeting TGF-β Signaling in Cancer. Trends Cancer. 2017; 3(1):56-71. DOI: 10.1016/j.trecan.2016.11.008. View

Vijayan A, Guha D, Ameer F, Kaziri I, Mooney C, Bennett L . IGFBP-5 enhances epithelial cell adhesion and protects epithelial cells from TGFβ1-induced mesenchymal invasion. Int J Biochem Cell Biol. 2013; 45(12):2774-85. DOI: 10.1016/j.biocel.2013.10.001. View

Courthod G, Tucci M, Di Maio M, Scagliotti G . Papillary renal cell carcinoma: A review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015; 96(1):100-12. DOI: 10.1016/j.critrevonc.2015.05.008. View

Schneider M, Wolf E, Hoeflich A, Lahm H . IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol. 2002; 172(3):423-40. DOI: 10.1677/joe.0.1720423. View

Richter A, Lerner S, Schroppel B . Current state of combined kidney and pancreas transplantation. Blood Purif. 2011; 31(1-3):96-101. DOI: 10.1159/000321865. View

10.

Dahlfors G, Arnqvist H . Vascular endothelial growth factor and transforming growth factor-beta1 regulate the expression of insulin-like growth factor-binding protein-3, -4, and -5 in large vessel endothelial cells. Endocrinology. 2000; 141(6):2062-7. DOI: 10.1210/endo.141.6.7481. View

11.

Mandapalli P, Labala S, Jose A, Bhatnagar S, Janupally R, Sriram D . Layer-by-Layer Thin Films for Co-Delivery of TGF-β siRNA and Epidermal Growth Factor to Improve Excisional Wound Healing. AAPS PharmSciTech. 2016; 18(3):809-820. DOI: 10.1208/s12249-016-0571-6. View

12.

Firth S, Baxter R . Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23(6):824-54. DOI: 10.1210/er.2001-0033. View

13.

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

14.

Liu L, Wang J, Li X, Ma J, Shi C, Zhu H . MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma. Biochem Biophys Res Commun. 2015; 457(4):621-6. DOI: 10.1016/j.bbrc.2015.01.037. View

15.

Tetzlaff F, Fischer A . Control of Blood Vessel Formation by Notch Signaling. Adv Exp Med Biol. 2018; 1066:319-338. DOI: 10.1007/978-3-319-89512-3_16. View

16.

Chen J, Sun X, Shao R, Xu Y, Gao J, Liang W . VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int J Nanomedicine. 2017; 12:6075-6088. PMC: 5573052. DOI: 10.2147/IJN.S142739. View

17.

Motzer R, Rini B, Bukowski R, Curti B, George D, Hudes G . Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295(21):2516-24. DOI: 10.1001/jama.295.21.2516. View

18.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Muhlenberg T . DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res. 2013; 73(12):3661-70. PMC: 3694361. DOI: 10.1158/0008-5472.CAN-12-3839. View

19.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi A, Tanaseichuk O . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10(1):1523. PMC: 6447622. DOI: 10.1038/s41467-019-09234-6. View

20.

Sureshbabu A, Tonner E, Allan G, Flint D . Relative Roles of TGF-β and IGFBP-5 in Idiopathic Pulmonary Fibrosis. Pulm Med. 2011; 2011():517687. PMC: 3100084. DOI: 10.1155/2011/517687. View